INCY vs MXCT โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
INCY Captures Institutional Edge (2โ2 Pillars ยท 8โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Incyte Genomics Inc (INCY) driven by superior Valuation, Growth & Margin while MXCT counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, INCY trades at 13.3x Forward P/E with 32.2% operating margin (+14.0% YoY revenue) versus MXCT at N/M Forward P/E and -85.5% operating margin (+48.7% YoY). In options structure, INCY sits in CONSOLIDATION (37th %ile IV; Dealer Gamma Walls on Pro) against MXCT sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | INCY Revenue | MXCT Revenue | INCY Op. Margin | MXCT Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $1.88B | N/A | 6.9% | N/A | INCY |
| FY2019 | $2.16B | $10M | 18.6% | -93.7% | INCY |
| FY2020 | $2.67B | $20M | -9.9% | -71.6% | INCY |
| FY2021 | $2.99B | $20M | 19.6% | -84.3% | INCY |
| FY2022 | $3.39B | $30M | 17.1% | -95.2% | INCY |
| FY2023 | $3.70B | $20M | 16.8% | -247.7% | INCY |
| FY2024 | $4.24B | $20M | 1.4% | -230.5% | INCY |
| FY2025 | $5.14B | $20M | 29.5% | -247.6% | INCY |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | INCY | MXCT | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $23.6B | $132.2M | Larger Scale | INCY |
| Trailing P/E Ratio Valuation | 59.1x | N/M | Lower Multiple | INCY |
| Forward P/E Ratio Valuation | 13.3x | N/M | Lower Multiple | INCY |
| Revenue Growth (YoY) Growth | +14.0% | +48.7% | Higher Growth | MXCT |
| Operating Margin (TTM) Profitability | 32.2% | -85.5% | Higher Margin | INCY |
| Net Profit Margin Profitability | 6.7% | -81.4% | Higher Margin | INCY |
| Return on Equity (ROE) Capital Efficiency | 7.8% | -16.9% | Higher ROE | INCY |
| 52-Week Range Position Momentum | 58% ($89โ$133) | 63% ($1โ$2) | Stronger Trend | MXCT |
| Beta / 30D Volatility Risk Regime | 0.30ฮฒ ยท 31% Vol | 1.19ฮฒ ยท 96% Vol | Lower Realized Risk | INCY |
| Unified Institutional Score Composite Signal | 54.6 / 100 (HOLD) | 41.7 / 100 (SELL) | Higher Composite | INCY |